Study analysis · Nature Communications · 2026
This gene lets people grow 10% more muscle—without ever stepping foot in a gym.
Some people are born with a genetic glitch that makes them naturally more muscular and less fatty, and it doesn't hurt their heart or fertility.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study looked at people who were born with a special genetic change that makes their body make less of a protein called myostatin. These people tend to have more muscle and less fat, but that doesn't mean taking a drug to block myostatin will do the same thing — it just shows what happens naturally in some people.
What’s the bottom line?
Some people are born with tiny genetic glitches in a muscle-limiting gene called myostatin — this lets their muscles grow bigger and their fat shrink, without hurting their heart or fertility.
How strong is this study?
This is a super well-done study because they looked at over a million people, used fancy MRI scans to measure muscle and fat very accurately, and checked their results in different groups. That makes us trust the findings a lot — but remember, it's still just watching what happens naturally, not testing a medicine.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
25 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control groupno control group
- Sample size (n=1100000)+20/20
- Follow-upno follow-up reported
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 556 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an observational genetic association study using naturally occurring variants; it cannot establish causation because participants were not randomized to genetic variants, and confounding factors (e.g., environmental, lifestyle, or other genetic factors) may influence the observed associations.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding disclosures were reported in the provided text; the study appears to be an independent genetic analysis with no apparent industry involvement.
The study is based on large-scale genetic data from UK Biobank and uses automated deep learning models for image analysis. No author affiliations, funding sources, or conflict of interest statements are provided, so the absence of disclosures cannot be confirmed as intentional. However, no evidence of industry influence or bias is present in the methodology or results described.
Key takeaways
- 01
People with these gene variants have 5–8% more total muscle, up to 10%+ more in glutes, 10–30% less body fat, and stronger grip — with the most common variant (Ile225Thr) giving about 20% less muscle gain than rarer ones.
- 02
A 10% increase in glute muscle is like gaining the muscle mass of a small leg — significant for strength and metabolism, and seen without heart or fertility problems.
Surprising findings
- Myostatin variants were linked to lower left ventricular wall thickness—not higher, as feared.Many assumed blocking myostatin would cause dangerous heart thickening (like in animal studies), but humans with lifelong disruption showed the opposite trend.
- The most common variant (Ile225Thr) has a much smaller effect than rare ones, yet still produces a statistically significant result.It suggests even mild, naturally occurring myostatin inhibition can shift body composition—meaning the pathway is exquisitely sensitive to tiny changes.
Practical takeaways
If you're on GLP-1 weight loss drugs like Ozempic, ask your doctor about muscle-preserving strategies—this study suggests myostatin blockers may soon be an option.
These findings are from natural genetic variants—drugs may have different effects, especially if used in adulthood rather than lifelong.
high confidenceWhy this study matters
Natural Muscle Boosters
People with rare MSTN gene variants have 5–8% more total skeletal muscle and over 10% more muscle in their glutes—equivalent to gaining the muscle mass of a small leg. This was confirmed via MRI scans of 77,572 people.
You don’t need steroids or intense training—some people just have biology on their side, and it’s linked to less body fat too.
Fat Loss Without Dieting
Carriers of these variants have significantly lower body fat percentage and reduced adipose tissue volume—without trying. The study found a reciprocal relationship: more muscle = less fat.
This challenges the idea that muscle gain and fat loss are always separate goals—some genes make them happen together.
No Heart or Fertility Risks
Despite fears that blocking myostatin could cause heart thickening or infertility, carriers showed no increased risk of cardiomyopathy, heart failure, or reproductive issues—including no changes in FSH levels, menarche, or live births.
This directly supports the safety of myostatin-blocking drugs currently in development for obesity and muscle loss.
The Ile225Thr Variant: A Mild Superpower
The most common variant, Ile225Thr (found in 0.19% of people), gives only 20% of the muscle gain seen in rarer variants—proving that even small reductions in myostatin have measurable effects.
It shows muscle growth isn’t all-or-nothing—tiny genetic tweaks can still make a difference.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Some people are born with tiny genetic glitches in a muscle-limiting gene called myostatin — this lets their muscles grow bigger and their fat shrink, without hurting their heart or fertility.
Research results
People with these gene variants have 5–8% more total muscle, up to 10%+ more in glutes, 10–30% less body fat, and stronger grip — with the most common variant (Ile225Thr) giving about 20% less muscle gain than rarer ones.
What this means - more context
A 10% increase in glute muscle is like gaining the muscle mass of a small leg — significant for strength and metabolism, and seen without heart or fertility problems.
This study investigates whether naturally occurring loss-of-function variants in the myostatin gene (MSTN) enhance muscle mass and reduce adiposity in humans, with implications for therapeutic myostatin blockade.
Analysis of 1.1 million individuals revealed that rare, function-disrupting MSTN variants are associated with increased skeletal muscle mass (5–8% overall, >10% in gluteal muscles), reduced body fat, greater grip strength, and no significant adverse effects on cardiac or reproductive health.
Methods Used
Multi-cohort genetic association analysis using exome sequencing from 1.1 million individuals, with deep phenotyping via whole-body MRI and automated deep learning segmentation in 77,572 UK Biobank participants; validation with BIA, DXA, and biomarker data.
Main Finding
Heterozygous carriers of rare, function-disrupting MSTN variants exhibit a 5–8% increase in total skeletal muscle mass and a 10% or greater increase in specific muscle groups (e.g., gluteus maximus), alongside reduced adiposity, with no increased risk of cardiomyopathy or reproductive dysfunction.
Confidence Level
High — large sample size, multi-cohort replication, direct MRI quantification, automated segmentation with high Dice scores (0.94–0.98), and dose-dependent effects across variants.
Study Flags
Red Flags
- •Lifelong genetic disruption may not mirror acute therapeutic blockade
- •Most variants are ultra-rare (AAF <0.19%), limiting generalizability
- •BIA-derived fat-free mass includes non-muscle components, though MRI validation mitigates this
Surprising Findings
Myostatin variants were linked to lower left ventricular wall thickness—not higher, as feared.
Many assumed blocking myostatin would cause dangerous heart thickening (like in animal studies), but humans with lifelong disruption showed the opposite trend.
Practical Takeaways
If you're on GLP-1 weight loss drugs like Ozempic, ask your doctor about muscle-preserving strategies—this study suggests myostatin blockers may soon be an option.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 556 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study looked at people who were born with a special genetic change that makes their body make less of a protein called myostatin. These people tend to have more muscle and less fat, but that doesn't mean taking a drug to block myostatin will do the same thing — it just shows what happens naturally in some people.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Extremely large sample size (1.1 million individuals)
- Use of multiple, high-precision phenotyping methods (MRI, DXA, BIA, biomarkers)
- Validation of findings across independent cohorts and measurement platforms
Weaknesses
- Observational design — cannot establish causation
- Genetic variants are not modifiable, so results do not directly predict therapeutic outcomes
- Lifelong exposure to variant effects may differ from adult-onset drug inhibition
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Some people are born with tiny genetic glitches in a muscle-limiting gene called myostatin — this lets their muscles grow bigger and their fat shrink, without hurting their heart or fertility.
Research results
People with these gene variants have 5–8% more total muscle, up to 10%+ more in glutes, 10–30% less body fat, and stronger grip — with the most common variant (Ile225Thr) giving about 20% less muscle gain than rarer ones.
What this means - more context
A 10% increase in glute muscle is like gaining the muscle mass of a small leg — significant for strength and metabolism, and seen without heart or fertility problems.
This study investigates whether naturally occurring loss-of-function variants in the myostatin gene (MSTN) enhance muscle mass and reduce adiposity in humans, with implications for therapeutic myostatin blockade.
Analysis of 1.1 million individuals revealed that rare, function-disrupting MSTN variants are associated with increased skeletal muscle mass (5–8% overall, >10% in gluteal muscles), reduced body fat, greater grip strength, and no significant adverse effects on cardiac or reproductive health.
Methods Used
Multi-cohort genetic association analysis using exome sequencing from 1.1 million individuals, with deep phenotyping via whole-body MRI and automated deep learning segmentation in 77,572 UK Biobank participants; validation with BIA, DXA, and biomarker data.
Main Finding
Heterozygous carriers of rare, function-disrupting MSTN variants exhibit a 5–8% increase in total skeletal muscle mass and a 10% or greater increase in specific muscle groups (e.g., gluteus maximus), alongside reduced adiposity, with no increased risk of cardiomyopathy or reproductive dysfunction.
Confidence Level
High — large sample size, multi-cohort replication, direct MRI quantification, automated segmentation with high Dice scores (0.94–0.98), and dose-dependent effects across variants.
Study Flags
Red Flags
- •Lifelong genetic disruption may not mirror acute therapeutic blockade
- •Most variants are ultra-rare (AAF <0.19%), limiting generalizability
- •BIA-derived fat-free mass includes non-muscle components, though MRI validation mitigates this
Surprising Findings
Myostatin variants were linked to lower left ventricular wall thickness—not higher, as feared.
Many assumed blocking myostatin would cause dangerous heart thickening (like in animal studies), but humans with lifelong disruption showed the opposite trend.
Practical Takeaways
If you're on GLP-1 weight loss drugs like Ozempic, ask your doctor about muscle-preserving strategies—this study suggests myostatin blockers may soon be an option.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 556 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study looked at people who were born with a special genetic change that makes their body make less of a protein called myostatin. These people tend to have more muscle and less fat, but that doesn't mean taking a drug to block myostatin will do the same thing — it just shows what happens naturally in some people.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Extremely large sample size (1.1 million individuals)
- Use of multiple, high-precision phenotyping methods (MRI, DXA, BIA, biomarkers)
- Validation of findings across independent cohorts and measurement platforms
Weaknesses
- Observational design — cannot establish causation
- Genetic variants are not modifiable, so results do not directly predict therapeutic outcomes
- Lifelong exposure to variant effects may differ from adult-onset drug inhibition
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This is a super well-done study because they looked at over a million people, used fancy MRI scans to measure muscle and fat very accurately, and checked their results in different groups. That makes us trust the findings a lot — but remember, it's still just watching what happens naturally, not testing a medicine.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
25 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control groupno control group
- Sample size (n=1100000)+20/20
- Follow-upno follow-up reported
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 556 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an observational genetic association study using naturally occurring variants; it cannot establish causation because participants were not randomized to genetic variants, and confounding factors (e.g., environmental, lifestyle, or other genetic factors) may influence the observed associations.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding disclosures were reported in the provided text; the study appears to be an independent genetic analysis with no apparent industry involvement.
The study is based on large-scale genetic data from UK Biobank and uses automated deep learning models for image analysis. No author affiliations, funding sources, or conflict of interest statements are provided, so the absence of disclosures cannot be confirmed as intentional. However, no evidence of industry influence or bias is present in the methodology or results described.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Physionic cite this study, drawing 2 claims from it.